CoChat

Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis

Chen, Ting-Ren, Huang, Hui-Chuan, Hsu, Jer-Hwa, Ouyang, Wen-Chen, Lin, Kuan-Chia · 2019 · Journal of Psychiatric Research
Cited by 54

The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.

Abstract

Generalized anxiety disorder (GAD) is a significant and common mental illness with a lifetime prevalence of 3.7%. Regardless of the complexity of treatment decisions for GAD, few studies have conducted systematic comparisons of the efficacies of varying interventions. Thus, this study performed a valid network meta-analysis (NMA) of randomized controlled trials (RCTs) to synthesize direct and indirect evidence for alternative interventions for GAD. We searched four major bibliographic databases, the Cochrane Central Register of Controlled Trials, Embase, PsycINFO, and PubMed, for published RCTs of adult patients with a diagnosis of GAD and allowed for all comorbidities. A total of 91 articles (14,812 participants) were identified in the final NMA. The results showed that all pharmacological treatments except for serotonin modulators and second-generation antipsychotics had greater effects than placebo: norepinephrine-dopamine reuptake inhibitors (standardized mean difference (SMD) -1.84, 95% credible interval -3.05 to -0.62), noradrenergic and specific serotonergic antidepressants (-0.91, -1.62 to -0.20), melatonergic receptor agonists (-0.68, -1.15 to -0.21), selective serotonin reuptake inhibitors (SSRIs; -0.67, -0.90 to -0.43), azapirones (-0.58, -1.00 to -0.17), anticonvulsants (-0.56, -0.85 to -0.28), serotonin-norepinephrine reuptake inhibitors (SNRIs; -0.54, -0.79 to -0.30), and benzodiazepines (BZDs; -0.40, -0.65 to -0.15). Most psychological and self-help interventions exerted greater effects than the waitlist group. However, no psychological interventions had greater effects compared with the psychological placebo. Overall, most pharmacological interventions had larger effect sizes than psychological interventions, and most psychological interventions showed larger effect sizes than self-help interventions.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.jpsychires.2019.08.014

Cites

44 of 44 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 44 references

Research works printed but not linked: 96

  1. Alaka, 2014, Efficacy and safety of duloxetine in the treatment of older adult patients with generalized anxiety disorder: a randomized, double-blind, placebo-controlled trial, Int. J. Geriatr. Psychiatry, 29, 978, 10.1002/gps.4088 · DOI · Paper page
  2. Aliyev, 2008, Valproate (depakine-chrono) in the acute treatment of outpatients with generalized anxiety disorder without psychiatric comorbidity: randomized, double-blind placebo-controlled study, Eur. Psychiatry, 23, 109, 10.1016/j.eurpsy.2007.08.001 · DOI · Paper page
  3. Allgulander, 2004, Efficacy of sertraline in a 12-week trial for generalized anxiety disorder, Am. J. Psychiatry, 1642, 10.1176/appi.ajp.161.9.1642 · DOI · Paper page
  4. Andersson, 2012, Internet-based psychodynamic versus cognitive behavioral guided self-help for generalized anxiety disorder: a randomized controlled trial, Psychother. Psychosom., 81, 344, 10.1159/000339371 · DOI · Paper page
  5. Antunes, 2018, Disability and common mental disorders: results from the world mental health survey initiative Portugal, Eur. Psychiatry : J. Assoc. Eur. Psychiatrists, 49, 56, 10.1016/j.eurpsy.2017.12.004 · DOI · Paper page
  6. Baldwin, 2006, Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study, Br. J. Psychiatry, 264, 10.1192/bjp.bp.105.012799 · DOI · Paper page
  7. Baldwin, 2011, Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis, BMJ, 342, d1199, 10.1136/bmj.d1199 · DOI · Paper page
  8. Bidzan, 2012, Vortioxetine (Lu AA21004) in generalized anxiety disorder: results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial, Eur. Neuropsychopharmacol., 22, 847, 10.1016/j.euroneuro.2012.07.012 · DOI
  9. Black, 2006, Efficacy of combined pharmacotherapy and psychotherapy versus monotherapy in the treatment of anxiety disorders, CNS Spectr., 11, 29, 10.1017/S1092852900025827 · DOI · Paper page
  10. Brawman-Mintzer, 2006, Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychiatry, 874, 10.4088/JCP.v67n0603 · DOI · Paper page
  11. Brenes, 2015, Telephone-delivered cognitive behavioral therapy and telephone-delivered nondirective supportive therapy for rural older adults with generalized anxiety disorder: a randomized clinical trial, JAMA Psychiatry, 72, 1012, 10.1001/jamapsychiatry.2015.1154 · DOI · Paper page
  12. Brown, 2015, Temporal profile of brain response to alprazolam in patients with generalized anxiety disorder, Psychiatry Res., 394, 10.1016/j.pscychresns.2015.06.016 · DOI
  13. Bystritsky, 2008, A pilot controlled trial of bupropion XL versus escitalopram in generalized anxiety disorder, Psychopharmacol. Bull., 46
  14. Chen, 2006, A comparative study of paroxetine and alprazolam in the treatment of patients with generalized anxiety disorder, J. heze Med. Coll., 18
  15. Christensen, 2014, The effectiveness of an online e-health application compared to attention placebo or Sertraline in the treatment of Generalised Anxiety Disorder, Internet Interv., 1, 169, 10.1016/j.invent.2014.08.002 · DOI
  16. Conrad, 2008, The psychophysiology of generalized anxiety disorder: 2. Effects of applied relaxation, Psychophysiology, 377, 10.1111/j.1469-8986.2007.00644.x · DOI
  17. Correll, 2011, Antipsychotic drugs and obesity, Trends Mol. Med., 17, 97, 10.1016/j.molmed.2010.10.010 · DOI · Paper page
  18. Crits-Christoph, 2011, Combined medication and cognitive therapy for generalized anxiety disorder, J. Anxiety Disord., 25, 1087, 10.1016/j.janxdis.2011.07.007 · DOI
  19. Davidson, 1999, Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder, J. Clin. Psychiatry, 528, 10.4088/JCP.v60n0805 · DOI · Paper page
  20. Davidson, 2004, Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study, Depress. Anxiety, 234, 10.1002/da.10146 · DOI · Paper page
  21. Diefenbach, 2016, Repetitive transcranial magnetic stimulation for generalised anxiety disorder: a pilot randomised, double-blind, sham-controlled trial, Br. J. Psychiatry, 209, 222, 10.1192/bjp.bp.115.168203 · DOI · Paper page
  22. Dilkov, 2017, Repetitive transcranial magnetic stimulation of the right dorsal lateral prefrontal cortex in the treatment of generalized anxiety disorder: a randomized, double-blind sham controlled clinical trial, Prog. Neuro Psychopharmacol. Biol. Psychiatry, 78, 61, 10.1016/j.pnpbp.2017.05.018 · DOI
  23. Dimitriou, 1992, Buspirone vs alprazolam: a double-blind comparative study of their efficacy, adverse effects and withdrawal symptoms, Drug Invest., 316, 10.1007/BF03259411 · DOI
  24. Durgam, 2016, Efficacy and Safety of Vilazodone in Patients With Generalized Anxiety Disorder: A Randomized, Double-Blind, Placebo-Controlled, Flexible-Dose Trial, J. Clin. Psychiatry, 77, 1687, 10.4088/JCP.15m09885 · DOI · Paper page
  25. Durham, 1994, Cognitive therapy, analytic psychotherapy and anxiety management training for generalised anxiety disorder, Br. J. Psychiatry, 315, 10.1192/bjp.165.3.315 · DOI · Paper page
  26. Feighner, 1995, Cardiovascular safety in depressed patients: focus on venlafaxine, J. Clin. Psychiatry, 56, 574
  27. Feltner, 2003, A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder, J. Clin. Psychopharmacol., 240, 10.1097/01.jcp.0000084032.22282.ff · DOI · Paper page
  28. Freiesleben, 2015, A systematic review of agomelatine-induced liver injury, J. Mol. Psychiatry, 3, 4, 10.1186/s40303-015-0011-7 · DOI
  29. Fulton, 1997, Buspirone: an updated review of its clinical pharmacology and therapeutic applications, CNS Drugs, 7, 68, 10.2165/00023210-199707010-00007 · DOI
  30. Gao, 2017, A placebo controlled study of quetiapine-XR in bipolar depression accompanied by generalized anxiety with and without a recent history of alcohol and cannabis use, Psychopharmacology, 234, 2233, 10.1007/s00213-017-4642-5 · DOI
  31. Gommoll, 2015, A double-blind, randomized, placebo-controlled, fixed-dose phase iii study of vilazodone in patients with generalized anxiety disorder, Depress. Anxiety, 32, 451, 10.1002/da.22365 · DOI · Paper page
  32. Gommoll, 2015, Vilazodone in patients with generalized anxiety disorder: a double-blind, randomized, placebo-controlled, flexible-dose study, Int. Clin. Psychopharmacol., 30, 297, 10.1097/YIC.0000000000000096 · DOI · Paper page
  33. Hamer, 2011, Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey, Eur. Heart J., 32, 437, 10.1093/eurheartj/ehq438 · DOI · Paper page
  34. Hamilton, 1959, The assessment of anxiety states by rating, Br. J. Med. Psychol., 32, 50, 10.1111/j.2044-8341.1959.tb00467.x · DOI · Paper page
  35. Hartford, 2007, Duloxetine as an SNRI treatment for generalized anxiety disorder: results from a placebo and active-controlled trial, Int. Clin. Psychopharmacol., 22, 167, 10.1097/YIC.0b013e32807fb1b2 · DOI · Paper page
  36. Holoubek, 2003, Specific modulation of sigma binding sites by the anxiolytic drug opipramol, J. Neural Transm., 110, 1169, 10.1007/s00702-003-0019-5 · DOI
  37. Huang, 2006, A comparison study of sertraline, venlafaxine and alprazolam in treatment of generalized anxiety disorder, Chin. J. Behav. Med. Sci., 376, 332
  38. Ji, 2004, Randomized, double blind controlled trial of trazodone versus alprazolam in the treatment of generalized anxiety disorder, Chin. J. Evidence-Based Med., 528
  39. Jiang, 2010, Randomized controlled trial of mono-therapy quetiapine versus mono-therapy paroxetine in the treatment of generalized anxiety disorder, Shanghai Arch. Psychiatry, 22, 295
  40. Kanwar, 2013, The association between anxiety disorders and suicidal behaviors: a systematic review and meta-analysis, Depress. Anxiety, 30, 917
  41. Kasper, 2009, Efficacy of pregabalin and venlafaxine-XR in generalized anxiety disorder: results of a double-blind, placebo-controlled 8-week trial, Int. Clin. Psychopharmacol., 24, 87, 10.1097/YIC.0b013e32831d7980 · DOI · Paper page
  42. Kasper, 2014, Pregabalin long-term treatment and assessment of discontinuation in patients with generalized anxiety disorder, Int. J. Neuropsychopharmacol., 17, 685, 10.1017/S1461145713001557 · DOI
  43. Keefe, 2014, A meta-analytic review of psychodynamic therapies for anxiety disorders, Clin. Psychol. Rev., 34, 309, 10.1016/j.cpr.2014.03.004 · DOI
  44. Laporte, 2017, Bleeding risk under selective serotonin reuptake inhibitor (SSRI) antidepressants: a meta-analysis of observational studies, Pharmacol. Res., 118, 19, 10.1016/j.phrs.2016.08.017 · DOI · Paper page
  45. Lenze, 2009, Escitalopram for older adults with generalized anxiety disorder: a randomized controlled trial, JAMA, J. Am. Med. Assoc., 301, 295, 10.1001/jama.2008.977 · DOI · Paper page
  46. Li, 2004, A comparison study of citalopram versus alprazolam in the treatment of generalized anxiety disorder, Shandong Arch. Psychiatr., 87
  47. Li, 2004, Tandospirone for treatment of generalized anxiety: a randomized, double blind and controlled study on the curative effect and reliability, Chin. J. Clin. Rehabil., 4176
  48. Li, 2005, A comparison study of sertraline versus alprazolam in the treatment of generalized anxiety disorder, Shandong Arch. Psychiatr., 145
  49. Li, 2005, A comparative study of paroxetine and clonazepam in the treatment of patients with generalized anxiety disorder, Shandong Arch. Psychiatr., 252
  50. Li, 2016, A randomized, placebo-controlled pilot study of quetiapine-XR monotherapy or adjunctive therapy to antidepressant in acute major depressive disorder with current generalized anxiety disorder, Psychopharmacol. Bull., 46, 8
  51. Lieb, 2005, The epidemiology of generalized anxiety disorder in Europe, Eur. Neuropsychopharmacol. : J. Eur. Coll. Neuropsychopharmacol., 15, 445, 10.1016/j.euroneuro.2005.04.010 · DOI · Paper page
  52. Linden, 2005, Efficacy of cognitive behaviour therapy in generalized anxiety disorders. Results of a controlled clinical trial (Berlin CBT-GAD Study), Psychother. Psychosom., 36, 10.1159/000082025 · DOI · Paper page
  53. Liu, 2005, A comparative study between mirtazapine and buspirone in the treatment of generalized anxiety disorder, Med. J. Chin. Health People, 495
  54. Mahableshwarkar, 2014, A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder, Int. J. Clin. Pract., 68, 49, 10.1111/ijcp.12328 · DOI · Paper page
  55. Mahableshwarkar, 2014, A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2.5 and 10 mg in acute treatment of adults with generalized anxiety disorder, Hum. Psychopharmacol., 29, 64, 10.1002/hup.2371 · DOI · Paper page
  56. Meyer, 1990, Development and validation of the Penn state worry Questionnaire, Behav. Res. Ther., 28, 487, 10.1016/0005-7967(90)90135-6 · DOI · Paper page
  57. Mokhber, 2010, Randomized, single-blind, trial of sertraline and buspirone for treatment of elderly patients with generalized anxiety disorder, Psychiatry Clin. Neurosci., 64, 128, 10.1111/j.1440-1819.2009.02055.x · DOI · Paper page
  58. Möller, 2001, Opipramol for the treatment of generalized anxiety disorder: a placebo-controlled trial including an alprazolam-treated group, J. Clin. Psychopharmacol., 21, 59, 10.1097/00004714-200102000-00011 · DOI · Paper page
  59. Montgomery, 2006, Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: a 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine, J. Clin. Psychiatry, 771, 10.4088/JCP.v67n0511 · DOI · Paper page
  60. Montgomery, 2008, Efficacy and safety of pregabalin in elderly people with generalised anxiety disorder, Br. J. Psychiatry, 193, 389, 10.1192/bjp.bp.107.037788 · DOI · Paper page
  61. Nicolini, 2009, Improvement of psychic and somatic symptoms in adult patients with generalized anxiety disorder: examination from a duloxetine, venlafaxine extended-release and placebo-controlled trial, Psychol. Med., 267, 10.1017/S0033291708003401 · DOI · Paper page
  62. Nimatoudis, 2004, Remission rates with venlafaxine extended release in Greek outpatients with generalized anxiety disorder. A double-blind, randomized, placebo controlled study, Int. Clin. Psychopharmacol., 331, 10.1097/00004850-200411000-00003 · DOI · Paper page
  63. Niu, 2004, Comparison of efficacy of mirtazapine and fluoxetine in treatment of depression with generalized anxiety disorder, Chin. J. N. Drugs Clin. Remedies, 853
  64. Pae, 2015, Vortioxetine, a multimodal antidepressant for generalized anxiety disorder: a systematic review and meta-analysis, J. Psychiatr. Res., 64, 88, 10.1016/j.jpsychires.2015.02.017 · DOI
  65. Peng, 2006, A controlled study of paroxetine and flunipam in the treatment of generalized anxiety disorder, J. Clin. Psychosom. Dis., 169
  66. Pohl, 2005, Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing, J. Clin. Psychopharmacol., 151, 10.1097/01.jcp.0000155820.74832.b0 · DOI · Paper page
  67. Ramchandran, 1990, Comparative clinical evaluation of buspirone and diazepam in generalized anxiety disorders, Curr. Ther. Res. Clin. Exp., 502
  68. Reinhold, 2015, Pharmacological treatment for generalized anxiety disorder in adults: an update, Expert Opin. Pharmacother., 16, 1669, 10.1517/14656566.2015.1059424 · DOI · Paper page
  69. Revicki, 2012, Humanistic and economic burden of generalized anxiety disorder in North America and Europe, J. Affect. Disord., 140, 103, 10.1016/j.jad.2011.11.014 · DOI · Paper page
  70. Richards, 2016, Effectiveness of an internet-delivered intervention for generalized anxiety disorder in routine care: a randomised controlled trial in a student population, Internet Interv., 6, 80, 10.1016/j.invent.2016.10.003 · DOI
  71. Rickels, 1993, Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam, Arch. Gen. Psychiatr., 50, 884, 10.1001/archpsyc.1993.01820230054005 · DOI · Paper page
  72. Rickels, 2003, Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study, Am. J. Psychiatry, 749, 10.1176/appi.ajp.160.4.749 · DOI · Paper page
  73. Rickels, 2005, Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam, Arch. Gen. Psychiatr., 1022, 10.1001/archpsyc.62.9.1022 · DOI · Paper page
  74. Rocca, 1997, Paroxetine efficacy in the treatment of generalized anxiety disorder, Acta Psychiatr. Scand., 95, 444, 10.1111/j.1600-0447.1997.tb09660.x · DOI · Paper page
  75. Roose, 2016, Selective serotonin reuptake inhibitors and operative bleeding risk: a review of the literature, J. Clin. Psychopharmacol., 36, 704, 10.1097/JCP.0000000000000575 · DOI
  76. Rosenthal, 2003, Tiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive control, J. Clin. Psychiatry, 1245, 10.4088/JCP.v64n1016 · DOI
  77. Ross, 1987, A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder, Can. J. Psychiatr. Rev. Canad. Psychiatr., 351, 10.1177/070674378703200505 · DOI · Paper page
  78. Rothschild, 2012, Vortioxetine (Lu AA21004) 5mg in generalized anxiety disorder: results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States, Eur. Neuropsychopharmacol., 22, 858, 10.1016/j.euroneuro.2012.07.011 · DOI
  79. Shen, 1999, Clinical study on buspirone hydrochloride treated for generalized anxiety disorder, J. Chin. Civil Adm. Med., 70
  80. Shi, 2004, Venlafaxine compared to alprazolam in the treatment of generalized anxiety disorder, Shanghai Arch. Psychiatr., 215
  81. Spitzer, 2006, A brief measure for assessing generalized anxiety disorder: the GAD-7, Arch. Intern. Med., 166, 1092, 10.1001/archinte.166.10.1092 · DOI · Paper page
  82. Stanley, 2003, Cognitive-behavior therapy for late-life generalized anxiety disorder in primary care: preliminary findings, Am. J. Geriatr. Psychiatry, 92
  83. Stein, 2015, CLINICAL PRACTICE. Generalized anxiety disorder, N. Engl. J. Med., 373, 2059, 10.1056/NEJMcp1502514 · DOI · Paper page
  84. Stein, 2008, Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study, J. Clin. Psychopharmacol., 28, 561, 10.1097/JCP.0b013e318184ff5b · DOI · Paper page
  85. Stein, 2017, Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: a 12-week, double-blind, placebo-controlled study, Eur. Neuropsychopharmacol., 27, 526, 10.1016/j.euroneuro.2017.02.007 · DOI · Paper page
  86. Taylor, 2008, Antidepressant drugs and cardiovascular pathology: a clinical overview of effectiveness and safety, Acta Psychiatr. Scand., 118, 434, 10.1111/j.1600-0447.2008.01260.x · DOI · Paper page
  87. Wang, 2003, A comparative study between venlafaxine and alprazolam in the treatment of generalized anxiety disorder, J. Clin. Psychol. Med., 155
  88. Wang, 2004, A clinical control study of paroxetine and clonazepam in the treatment of generalized anxiety disorder, Chin. J. Psychol. Health, 359, 365
  89. Weizhen, 2004, A comparative study of paroxetine and lorazepam in the treatment of generalized anxiety disorder, Chin. Ment. Health J., 18, 740
  90. Wetherell, 2003, Treatment of generalized anxiety disorder in older adults, J. Consult. Clin. Psychol., 31, 10.1037/0022-006X.71.1.31 · DOI · Paper page
  91. Wu, 2011, Duloxetine versus placebo in the treatment of patients with generalized anxiety disorder in China, Chin. Med. J., 124, 3260
  92. Yin, 2005, The clinical comparison of citalopram with estazolam in the efficacy for generalized anxiety disorder, J. Jinggangshan Univ., 105
  93. Zareifopoulos, 2017, Efficacy and tolerability of vilazodone for the acute treatment of generalized anxiety disorder: a meta-analysis, Asian J. Psychiatr, 26, 115, 10.1016/j.ajp.2017.01.016 · DOI
  94. Zargar, 2012, Effect of acceptance-based behavior therapy on severity of symptoms, worry and quality of life in women with generalized anxiety disorder, Iran. J. Psychiatry Behav. Sci., 6, 23
  95. Zeng, 2003, Paroxetine versus alprazolam in treatment of generalized anxiety disorder, Sichuan Ment. Health, 135
  96. Zullino, 2015, Venlafaxine versus applied relaxation for generalized anxiety disorder: a randomized controlled study on clinical and electrophysiological outcomes, Psychiatr. Q., 86, 69, 10.1007/s11126-014-9334-2 · DOI

Cited by

See all 54

Metadata

Authors
Chen, T.-R., Huang, H.-C., Hsu, J.-H., Ouyang, W.-C., & Lin, K.-C.
Venue
Journal of Psychiatric Research
Publisher
Elsevier BV
Published
2019-11
Volume
118
Pages
73-83
ISSN
0022-3956 (ISSN-L)
OpenAlex
W2971709403
Cited by
54
References
44
FWCI
8.39
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. https://app.cochat.ai/papers/10.1016/j.jpsychires.2019.08.014
The paper
Chen, T.-R., Huang, H.-C., Hsu, J.-H., Ouyang, W.-C., & Lin, K.-C. (2019). Pharmacological and psychological interventions for generalized anxiety disorder in adults: A network meta-analysis. Journal of Psychiatric Research. https://doi.org/10.1016/j.jpsychires.2019.08.014

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.